Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858679 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4DRD2DRD3ALDH1A1 | |
| SCHEMBL1858682 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4DRD2DRD3ALDH1A1 | |
| SCHEMBL1858677 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4DRD2DRD3ALDH1A1 | |
| SCHEMBL5511678 | 0.96 | SLC6A2 (0.53) | SLC6A2SLC6A4DRD2DRD3SLC6A3 | |
| SCHEMBL5511676 | 0.96 | SLC6A2 (0.53) | SLC6A2SLC6A4DRD2DRD3SLC6A3 | |
| SCHEMBL1860481 | 0.85 | REN (0.48) | SLC6A2SLC6A4SLC6A3RENCYP2D6 | |
| SCHEMBL3593314 | 0.85 | REN (0.48) | SLC6A2SLC6A4SLC6A3RENCYP2D6 | |
| SCHEMBL1860479 | 0.85 | REN (0.48) | SLC6A2SLC6A4SLC6A3RENCYP2D6 | |
| SCHEMBL1860476 | 0.85 | REN (0.48) | SLC6A2SLC6A4SLC6A3RENCYP2D6 | |
| SCHEMBL969536 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | SLC6A2 3389/4885SLC6A4 3809/4885DRD2 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.